Events
CGuard™ EPS clinical data featured as a prominent discussion point in multiple key presentations
Replimune Group Inc. announced that Philip Astley-Sparke, Executive Chairman and Director of Replimune, will present and host investor meetings at the Piper Jaffray 31st Annual Healthcare Conference being held at the Lotte New York Palace in New York, NY.
Gritstone Oncology announced that Andrew Allen, M.D., Ph.D., co-founder, president and chief executive officer, will present a company overview on Tuesday, December 3, 2019 at 8:30 a.m. ET during the Piper Jaffray 31st Annual Healthcare Conference in New York..
miRagen Therapeutics, Inc. announced that management will be presenting at the Evercore ISI HealthCONx Conference 2019 on Tuesday, December 3rd, taking place at the Four Seasons Hotel in Boston, Massachusetts.
Neoleukin Therapeutics, Inc. “Neoleukin” announced that Jonathan Drachman, M.D., Chief Executive Officer, will present at the Piper Jaffray 31st Annual Healthcare Conference on Thursday, December 5, 2019 at 2:50 p.m. EST in New York.
Krystal Biotech Inc. announced that Krish S. Krishnan, chairman and chief executive officer, will present at the Piper Jaffray 31st Annual Healthcare Conference in New York City being held Dec. 3-5 in New York.
Intellia Therapeutics, Inc., a leading genome editing company focused on developing curative therapeutics using CRISPR/Cas9 technology both in vivo and ex vivo, will present at the Evercore ISI 2nd Annual HealthCONx Conference on Tuesday, December 3, 2019 at 8:20 a.m. ET in Boston, MA..
Ovid Therapeutics Inc. announced that Amit Rakhit, M.D., President and Chief Medical Officer, will participate in an analyst-led fireside chat at the 31st Annual Piper Jaffray Healthcare Conference on Wednesday, December 4, 2019, at 4:00 p.m. EST.
Harpoon Therapeutics, Inc. announced that Gerald McMahon, Ph.D., President and Chief Executive Officer, will participate in a fireside chat at the 31st Annual Piper Jaffray Healthcare Conference.
Apellis Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company focused on the development of novel therapeutic compounds to treat disease through the inhibition of the complement system, announced that the company will participate in the following upcoming investor conferences in December
PRESS RELEASES